NCT00373243View on ClinicalTrials.gov

A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 19, 2005

Primary Completion Date

September 26, 2006

Study Completion Date

September 26, 2006

Conditions
Pain
Interventions
DRUG

GW406381

GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.

Trial Locations (2)

1062

GSK Investigational Site, Budapest

8230

GSK Investigational Site, Balantonfured

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00373243 - A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter